Trials / Completed
CompletedNCT05295875
Efficacy and Safety of ALT-801 in the Treatment of Obesity
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 391 (actual)
- Sponsor
- Altimmune, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALT-801 | Injected subcutaneously (SC) |
| OTHER | Placebo | Injected subcutaneously (SC) |
Timeline
- Start date
- 2022-03-31
- Primary completion
- 2023-09-28
- Completion
- 2023-09-28
- First posted
- 2022-03-25
- Last updated
- 2023-11-29
Locations
31 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05295875. Inclusion in this directory is not an endorsement.